Previous work has shown that the 68-kDa immediate-early protein of herpes simplex virus type 1 (HSV-1), also known as ICP22, is involved in the control of viral gene expression, although the precise mechanism remains to be elucidated. In order to study the function(s) of this protein, we constructed expression vectors containing the coding sequence of the ICP22 gene placed under the control of the SV40 or HCMV promoter. After cell transfection, ICP22 synthesis was studied by immunoblotting, using a specific antiserum. In transient expression experiments in COS cells in which the ICP22 vector was under the control of the SV40 promoter, we found that ICP22 was able to inhibit chloramphenicol acetyltransferase (CAT) expression under the control of either the a22 (IE4) promoter or other immediate-early promoters, such as a4 (IE3), a0 (IE1), and a27 (IE2). CAT expression under the control of the a4 (IE3) promoter was inhibited in these cells by expression of ICP22 under the control of the HCMV promoter; it was also inhibited in RAT-1 cells by ICP22 expressed under the control of the SV40 or HCMV promoter. In contrast, CAT expression directed by the SV40 or HCMV promoters was only weakly or not inhibited by the ICP22 vectors. We also constructed an expression vector for UL13, a gene whose product is implicated in the phosphorylation of ICP22. Although CAT expression under the control of the a4 (IE3) promoter was also negatively regulated by the UL13 gene product, the effects of the ICP22 (directed by the SV40 or HCMV promoter) and UL13 vectors were not synergistic; furthermore, at a particular molar ratio of the two vectors, inhibition of CAT activity was partially reversed. The results in the present work suggest that ICP22 can negatively regulate the expression of immediate-early viral genes and that its phosphorylation by UL13 protein kinase might be involved in the modulation of its function. ᭧ 1996 Academic Press, Inc.
INTRODUCTION
a major role in reactivation from latency (Cai et al., 1993) (for review, see Roizman and Sears, 1991) .
In cells lytically infected with herpes simplex virus
The situation with regard to ICP22 is not entirely clear. type-1 (HSV1), the first genes to be transcribed are desigIn transient transfection assays, ICP22, both alone and nated a, or immediate-early (IE), genes and encode five in combination with other immediate-early proteins, proteins, designated ICP0, 4, 22, 27, and 47. Genetic shows no ability to transactivate HSV1 promoters (O'Hare studies have shown that the genes coding for ICP4 and and Hayward, 1985) . However, in certain cell lines in-27 are essential for viral growth and exert a regulatory fected with a virus containing a deletion in the ICP22 role. ICP4 is the major protein involved in transcription gene, late gene expression is reduced, suggesting a cellregulation in HSV-1 (Mackem and Roizman, 1982 ; Deluca type-dependent role for this protein in the activation of et Gelman and Silverstein, 1987) ; it is necessary this class of genes (Sears et al., 1985) . More recently, during infection for the activation of the b, or early (E), ICP22 has been implicated in the modification of the host and g, or late (L), genes (Watson and Clements, 1980) RNA polymerase II (Rice et al., 1995) . The ICP22 gene and also represses the expression of all the a genes has some interesting characteristics. Its regulatory se-(O' Hare and Hayward, 1985) . ICP27 appears to mediate quences, shared with the ICP47 gene, overlap those of the transition from the b to the g phase of viral infection the ICP4 gene and of the viral origin of replication, OriS. and also transactivates g genes and represses a and b
The gene consists of two exons and one intron, the entire genes, in combination with ICP4 and ICP0 (Sekulovich coding sequence being located in exon 2 in the unique et al., 1988) . Other IE genes are not essential for viral short sequence of the HSV-1 genome. The protein is growth in all cell types, but have been implicated as guanylated, adenylated, and phosphorylated, and at least playing a role in gene expression. In particular, ICP0 part of these posttranslational modifications involve the transactivates a, b, and g genes and is thought to play viral protein kinases encoded by UL13 and US3 and casein kinase II (Purves and Roizman, 1992; Blaho et al., 1993; Purves et al., 1993; Mitchell et al., 1994) . To study which the coding sequences of ICP22 and UL13 were promoter, was obtained from Dr. G. Tiraby (Baron et al., 1992) . placed under the control of the SV40 and/or HCMV promoters. Using transient expression assays, we then anaTransfection assays lyzed the effects of ICP22 vectors on IE viral gene expression in the presence and absence of UL13. The results Cells (0.6 1 10 6 ) were seeded in cell culture flasks indicate that ICP22 can repress the expression of CAT and then transfected 8 hr later, using the calcium method directed by IE promoters, including the a22 promoter, (Graham and Van Der Eb, 1973) or lipofectamine (Gibcoand that this inhibition can be partially reversed by the BRL), with 15 mg of herring sperm (HS) DNA or a mixture UL13 vector at a particular molar ratio of the two vectors.
of plasmid DNAs (15 mg of DNA) plus HS.
MATERIALS AND METHODS Immunoblotting
Cells, virus, and viral DNA Cells were transfected with plasmid DNA, as previously described. Twenty and 72 hr after transfection, COS and Vero cell lines were obtained from the Amerithey were washed with PBS and then sonicated, and the can Type Culture Collection and Rat-1 was from Weindebris was removed by centrifugation. The proteins in berg's laboratory (MIT, Cambridge, MA). HSV1(F) (Heine the supernatant were separated by electrophoresis on et al., 1974) was provided by Dr. B. Roizman (University 10% SDS-polyacrylamide gels, transferred electrophoof Chicago). Viral DNA was purified from the cytoplasm retically to nitrocellulose membranes, then washed with of infected Vero cells by banding in Nal equilibrium gradiwater. To prevent nonspecific antibody binding, the mements (Walboomers and Ter Scheggett, 1976) .
brane was treated with 5% fat-free milk in PBS, before being incubated for 1 hr with a specific rabbit anti-ICP22 Construction of plasmids antiserum provided by B. Roizman (Ackerman et al., 1985) . The blots were washed three times with PBS conThe fragment BamHI-BstEII, containing the a22 gene taining 0.2% Triton X-100 and then incubated for 1 hr with (pBN/1) (Garcin et al., 1990) , was subcloned into pBluegoat anti-rabbit immunoglobulin antibodies conjugated script (SK, Stratagene) between the EcoRI and ClaI reto alkaline phosphatase. After three washes as above, striction sites. The 5 noncoding sequence of this gene, the color reaction was developed using nitroblue tetrazoincluding the first exon and part of the intron, was deleted lium (Sigma) and 5-bromo-4-chloro-3-indolyl phosphate by exonuclease III and mung bean nuclease digestion.
(Sigma) as substrates (Garcin et al., 1990) . Various deleted plasmids were isolated and sequenced and one, designated p22, containing eight additional nu-CAT and LacZ assays cleotides outside the open reading frame, was selected for further cloning. The fragment BamHI-SalI, containing Seventy-two or 96 hr after transfection, the cell lysates the a22 gene, was filled in with Klenow enzyme and were analyzed for CAT activity, as described by Gorman cloned at the SmaI site of plasmid pcEXV3 (Miller and et al. (1982) , using 0.2 mCi of [ 14 C]chloramphenicol (60 Germain, 1986) (referred to as pEX), downstream of the mCi/mmol, NEN). All quantitative comparisons were SV40 promoter; the product was designated pEX22.
made by measuring the mono-and diacetylated derivapCMV/CAT (Foecking and Hofstetter, 1986) was digested tives of chloramphenicol on the linear part of the prodwith HindIII and EcoRI to delete the CAT cDNA. Following uct-enzyme concentration graphs. LacZ activity was deKlenow treatment, the filled ends were either directly termined colorimetrically by the absorbance at 570 nm ligated, producing pCMV, or ligated to the blunt-ended using chlorophenol red-b-D-galactopyranoside (CPRG) BamHI-SalI fragment described above, producing as substrate (Eustice et al., 1991) . pCMV22. To construct the UL13 vector, a BglII fragment from HSV1 (F) DNA (Perry and McGeoch, 1988) was
In vitro transcription and translation and cloned into the BamHI site of SK plasmid. A KpnI fragimmunoprecipitation of the translation product ment was then deleted, producing pUL13, and a KpnIXbaI fragment was cloned into the SmaI site of pEX,
In vitro transcription reactions were performed in a volume of 50 ml containing 0.5 mg of pUL13 or p22 and placing UL13 under the control of the SV40 promoter. Finally, the region between the BalI and SpeI sites was using T3 or T7 polymerase, respectively, followed by in vitro translation in the presence of 40 mCi of [ 35 S]-deleted, producing pEXUL13.
The plasmids pIGA72, 65, 106, and 98, containing the methionine (1000 Ci/mmol, NEN). RNA and protein syntheses were carried out using TNT-coupled reticulocyte CAT gene under the respective control of the a4, 0, 22/ 47, and 27 regulatory-promoter sequences were oblysate systems (Promega), following the manufacturer's instructions. tained from S. Silverstein (Gelman and Silverstein, 1987). pSV2CAT (Gorman et al., 1982) was used as a control.
Immunoprecipitation of in vitro-translated UL13 protein was achieved using Staphylococcus aureus (Pansorbin, pUT535, containing LacZ under the control of the HCMV Calbiochem), previously activated in RIPA buffer (10% SDS, 0.1% Tween, 1% DOC, 0.15 M NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA, and 0.25 mM PMSF), diluted in the same buffer and immunoprecipitated with anti-UL13 polyclonal rabbit antiserum provided by A. Davidson (Cunningham et al., 1992) , as described by the authors.
Protein kinase assay
Proteins were extracted from the nuclei of mock-infected or HSV-1-infected cells and from pEX-or pEXUL13-transfected cells, using salt washes, followed by ammonium sulfate precipitation (Piette et al., 1985) . Nuclear extracts, or aliquots of previously washed immunoprecipitates (three times with PBS), were suspended in 50 ml of protein kinase buffer (20 mM Tris-HCl, pH 8, 1.5 M NaCl, 50 mM MgCl 2 , 1 mM dithiothreitol, 0.1% Nonidet washed three times with PBS buffer, boiled for 5 min in denaturing buffer, and analyzed by 10% SDS-polyacrylamide gels. To quantify the radioactivity in nuclear exThe ICP22 vector inhibits CAT expression from tracts, aliquots were precipitated with 10% TCA in the regulatory regions presence of cold ATP.
We then analyzed the regulation in COS cells of the RESULTS HSV-1 a4 promoter by the pEX22 and pCMV22 expression vectors, using a plasmid containing a4 regulatory Analysis of ICP22-encoding plasmids sequences upstream of the reporter CAT gene (pIGA72). Figure 2A shows the percentage of mono-and diace-COS cells were either infected with HSV1(F) or transfected with pCMV22, pEX22, or pBN/1, corresponding, tylated chloramphenicol produced versus the concentration of pEX22 or pCMV22 used; dose-dependent inhibirespectively, to the ICP22 coding sequence under the control of the HCMV, SV40, or natural promoter. Twentytion of CAT expression can be seen. Using 10 and 5 mg, respectively, of the vectors pEX and pCMV (lacking the four hours later, the cells were lysed and the soluble protein extracts analyzed by Western blots, using a spea22 coding sequence), there was essentially no inhibition of CAT activity (data not shown). cific anti-ICP22 antiserum (Fig. 1) .
Following transfection, the expression vectors conTo confirm that the inhibition of IE gene expression was specific, three further experiments were carried out. taining the HCMV or SV40 promoters produced detectable amounts of ICP22. Using the specific antibody, sevFirst, COS cells were transfected with pIGA72 plus a series of mixtures of pEX / pEX22 (2 mg total) or pCMV eral immunoreactive bands with apparent molecular weights between 70 and 90 kDa were seen in both Vero / pCMV22 (5 mg total), a protocol designed to add increasing amounts of the a22 coding region while keepand COS cells; more ICP22 was produced by the SV40 promoter-containing vector than by that containing the ing the total amount of regulatory region constant to ensure that any effects seen were due to ICP22 ORF; a HCMV promoter. Several higher molecular weights bands were also seen, although at a lower intensity than dose-dependent inhibition of CAT expression similar to that shown in Fig. 2A was observed (Fig. 2B) . No differin infected cells. In pCMV22-transfected COS cells, a weak 70-kDa immunoreactive band was seen. Under the ence between cells transfected with either pIGA72 alone or pIGA72 in the presence of pEX or pCMV was detected; control of its natural promoter (pBN1), no ICP22 synthesis was detectable, although the plasmid contains regulatory the percentages of acetylated CAT, before (Fig. 2B ) normalization, were 91.7 { 0.2 and 86.7 { 4.3%, with or sequences located both upstream (Roizman and Sears, 1991) and downstream (Greco et al., 1994) of the tranwithout pEX, and 93 { 0.5 and 89.2 { 2.1%, with or without pCMV, respectively, suggesting that the ICP22 scription initiation site. A faint nonspecific high molecular weight band was seen in all samples from COS-transvectors lacking the coding sequence have no effect on the a4 promoter. Second, the ability of increased fected cells.
FIG. 2.
Inhibition of CAT expression by ICP22 under the control of immediate-early or heterologous promoters. COS cells were cotransfected: (A) with 5 mg of pIGA72 (containing a4 promoter) and increased concentrations of pEX22 or pCMV22 as effectors; (B) with 5 mg of pIGA72, pCMVCAT, or pSV2CAT and 2 mg of the mixtures pEX/pEX22 or pCMV/pCMV22 as effectors. The circles represent the effect of pEX22 or pEX/pEX22 on PIGA72, the squares represent that of pCMV22 or pCMV/pCMV22 on pIGA72, the diamonds represent that of pEX/pEX22 on pCMVCAT, and the triangles represent that of pCMV/pCMV22 on pSV2CAT. The values shown are the percentage of acetylated chloramphenicol versus the concentration of the effector, ICP22 (pEX22 or pCMV22). Standard deviations are reported for 4 mg of expression vectors. The autoradiograms of the chromatograms for A are shown at the bottom of the figure. amounts of both plasmids (pEX22 and pCMV22) to inhibit 22/47, and 27, were tested with pEX22. Dose-dependent inhibition was again seen, being more efficient with the CAT expression driven by heterologous promoters in COS cells was evaluated under the same conditions (Fig. a0 promoter (pIGA65) than with either the a22/47 (pIGA106) or a27 (pIGA98) promoters (Fig. 3A) . 2B). With 4 mg of pEX22 on pCMVCAT and with 4 mg of pCMV22 on pSV2CAT, the results of three such experiFinally, the ability of ICP22 to inhibit CAT expression was tested using pIGA72 in the Rat-1 cell line, which ments shown in Fig. 2B , gave respective CAT activities of 93 { 2.5 and 89 { 5%, suggesting that the ICP22 cannot complement a lack of ICP22 (Sears et al., 1985) . The results, shown in Fig. 3B , demonstrate that, although vector could either not inhibit or only weakly inhibit heterologous promoters. Third, the same specificity was seen higher concentrations of plasmid were required, both pEX22 and pCMV22 were able to inhibit CAT expression for the HSV1 promoter in COS cells cotransfected with a mixture of CAT plasmid and LacZ plasmid under the from pIGA72 in these cells. Thus, the ICP22 vector can inhibit all IE promoters, including itself, and is effective respective control of the a4 promoter-regulatory region (pIGA72) and the HCMV promoter-regulatory region in two different cell types. (pUT535). LacZ expression, determined colorimetrically, was not affected by increasing concentrations of pXE22, A plasmid expressing the UL13 gene product inhibits the absorbance at 570 nm (using CPRG as substrate)
CAT expression from pIGA72 and can partly reverse varying between 0.70 and 0.79 for amounts of pEX22 the inhibitory effect of ICP22 ranging from 0 to 2 mg. Thus, ICP22 is able to specifically block the a4 promoter.
It has previously been noted that the protein kinase encoded by the UL13 gene of HSV1 can influence the Three other IE reporter plasmids, pIGA65, 106, and 98, which carry, respectively, regulatory sequences for a0, posttranslational processing associated with phosphory- lation of ICP22, thereby altering its function (Purves and Finally, the protein kinase activity of pEXUL13 was tested by its autophosphorylation by 32 P-labeled g-ATP . To study whether the UL13 gene product might exert an effect on the inhibitory effect of ICP22 on using nuclear extracts of COS cells transfected with 10 mg of either pEX or pEXUL13; the TCA precipitable radio-CAT expression, we constructed two vectors expressing UL13 under the control of either the T3 promoter (pUL13) activity was 3638 cpm/mg of protein for pEXUL13, 534 or the SV40 promoter (pEXUL13).
The pUL13 and p22 vectors, containing the coding sequences for UL13 and ICP22 directed by the T3 and T7 promoter, respectively, were transcribed in vitro and translated in the presence of [
35 S]methionine. The results (Fig. 4, left) show that, in the case of ICP22, three bands were seen, corresponding to three different open reading frames, the largest with the same molecular weight as ICP22 (lane 1), while, for UL13, three bands were also seen (lane 2), but, after immunoprecipitation with UL13-specific antiserum, only one band with a molecular weight of 57 kDa (identical to that of UL13) was detected (lane 3).
Aliquots of unlabeled UL13 immunoprecipitates were incubated with 32 P-labeled g-ATP in protein kinase buffer in the presence of casein, a known heterologous substrate for UL13 (Cunningham et al., 1992) or of in vitrotranslated ICP22 (Fig. 4, right) . Highly efficient phosphorylation of casein (lane 2) and weak autophosphorylation of UL13 were seen (lane 3). Various labeled bands, with pEXUL13 (lanes 2-4) , or pEX22 (lane 6) or various proportions of the mixtures pEX22/pEXUL13 (lanes 7-9) or pEX/pEXUL13 (lanes 10 and 11); (right) using lipofectamine with 1 mg of pIGA72 and various amounts of pCMV22 alone (lanes 13-15) or 1 mg of pCMV22 in combination with variable amounts of pEXUL13 (lanes 16 and 17) . The upper part of the figure shows the autoradiograms of chromatograms, while the percentages of acetylated chloramphenicol and pIGA72 inhibition are given below the figure. cpm/mg for pEX-transfected cells, 65,441 cpm/mg for ly-(columns 12-15). The 81% inhibition produced by 1 mg of pCMV22 fell to 58% on addition of 0.5 mg of pEXUL13 sates of infected cells (24 hr after infection with 20 PFU/ cell of HSV1), and 585 cpm/mg for lysates of uninfected (column 16). As in the previous experiment, increasing the amount of pEXUL13 resulted in further inhibition of cells. This high level of phosphorylation is relevant in terms of the stimulation of several protein kinases followpIGA72 (column 17). These observations suggest either that, at a certain specific ICP22/UL13 ratio, the UL13 ing viral infection (Lemaster and Roizman, 1980) . Since our UL13 vectors clearly expressed a functional vector can partially reverse the inhibitory effect of ICP22 on IE gene expression or that ICP22 can partially reverse protein kinase which was previously observed to phosphorylate ICP22 (Purves and Roizman, 1992) , the effect the inhibitory effect of UL13. on pIGA72 expression of the simultaneous presence in COS cells of the plasmids pEX22 and pEXUL13 was ana-DISCUSSION lyzed; the results are shown in Fig. 5 (left) . The UL13 gene product strongly inhibited CAT expression under Our data indicate that, under the experimental conditions used in this work, ICP22 inhibits CAT expression the control of a4 promoter, the effect being dose-dependent (columns 1 to 4). One microgram of UL13 vector under the control of HSV-1 IE promoters, including the a22 (IE4) promoter itself. The effect seems to be HSV1 (pEXUL13) inhibited pIGA72 activity by 76% (column 2), while the same amount of pEX22 gave 64% inhibition promoter-specific, since ICP22 did not inhibit the SV40 and HCMV promoters, and it occurred when the protein (column 6). The combination of 1 mg each of pEXUL13 and control plasmid pEX (column 10) resulted in 81% was expressed under the control of two different heterologous promoters (SV40 and HCMV) in two different cell inhibition, while that of 1 mg each of pEXUL13 and pEX22 (column 7) resulted in only 38% inhibition. When pEXUL13 lines (COS and Rat-1). Expression of, and inhibition by, ICP22 was greatest was present in excess over pEX22, the inhibition results were similar to those seen with pEXUL13 alone (columns when it was expressed in COS cells under the control of the SV40 promoter (pEX22), with 1 mg of pEX22 or 2 8 and 3, 9 and 4). A similar degree of reversal of ICP22 inhibition occurred when the amount of SV40 promoter mg of pCMV22 being sufficient to produce 50% inhibition of pIGA72 in these cells (Fig. 2B) . In Rat-1 cells, more driving ICP22 and UL13 was normalized for all samples using a plasmid containing only the SV40 promoter (pEX) pEX22 and pCMV22 were required to produce the same degree of inhibition (Fig. 3B) . The data in the two cell (data not shown). The mean inhibition produced by 5 mg of pIGA72 in three different experiments was 74 { 2.6% types were qualitatively similar, despite the fact that COS and Rat-1 cells differ in their ability to support the growth for 2 mg of pEX22, 77.7 { 2.4% for 1 mg of pEXUL13, and 10.3 { 2.3% for 2 mg of pEX22 in the presence of 1 mg of the ICP22-deleted mutant (Sears et al., 1985) . It is interesting to note that ICP22 and other alphaherof pEXUL13.
To confirm these results, pCMV22 and pEXUL13 were pesvirus ICP22-like proteins (PRV, RSp40; EHV1, IR4 ORF; BHV1, BICP22; and VZV, gene 63) show some structested in COS cells for their ability to inhibit CAT expression under the control of pIGA72; the results are shown tural homology in their central part, a possible DNA-binding region. The kinetics of the expression of ICP22 homoin Fig. 5 (right) . Increased inhibition of CAT expression was seen with increasing concentrations of pCMV22 logs differ during the course of infection. In the case of pseudorabies virus (PRV), the ICP22 homolog is an early undergoes partial phosphorylation of its carboxy-terminal domain (CTD), producing a form which is probably more gene (Zhang and Leader, 1990) ; in equine herpes virus 1 (EHV1), its homolog is expressed, under various proadapted to viral than to cellular transcription (Rice et al., 1994) . More recently, this modification has been shown moters, depending on the phase of the permissive cycle, first as an early gene, then as a g1 gene (Holden et al., to require ICP22 synthesis, but it was not possible to relate this to the cell-type-dependent growth phenotype 1992); in transient assays, it enhances the transactivation of IE, early, and late promoters when expressed in combiof ICP22-deleted mutants (Rice et al., 1995) . The authors suggest that the UL13 protein may be an ICP22-depennation with others transactivators (Holden et al., 1995) ; and in bovine herpes virus 1 (BHV1), BICP22 is expressed dent CTD kinase. Our data, and those of others, regarding the similarity of the phenotypes of UL13-and ICP22-with IE or L kinetics, under the control of a single promoter (Schwyzer et al., 1994) . According to cycloheximide deleted mutants suggest that UL13 can modify the phosphorylation of ICP22, and thus its experiments, only BICP22 and gene 63, the ICP22 counterpart in VZV, are regulated in the same way as ICP22 function, in a similar manner to CK2, which acts directly or indirectly on the regulation of many cellular or viral of HSV1 (Schwyzer et al., 1994; Debrus et al., 1995) . In transfection experiments, the gene 63 product inhibits IE genes (Meisner and Czech, 1991; Allende and Allende, 1995) . promoters (Jackers et al., 1992) . Although more recent experiments have not confirmed these results (Kost et ORF 47, the UL13 VZV homolog, although unable to phosphorylate ORF 63, the ICP22 homolog (Heineman al., 1995) , the similar kinetics of VZV and HSV1 ICP22 homologs might be related to similar functions during and Cohen, 1995) , can phosphorylate ORF 62, the ICP4 homolog (Ng et al., 1994) . Moreover, ORF 63 can be the IE infection stage.
The product of the UL13 gene, a serine-threonine prophosphorylated by protein kinase CK2 (Stevenson et al., 1996) . HSV1 ICP22 has 120 amino acids in its N-terminal tein kinase, is reported to be involved in ICP22 maturation (Purves and Roizman, 1992) . We therefore conregion, which are absent in the PRV, EHV1, BHV1, and VZV homologs (Zhang and Leader, 1990; Schwyzer et al., structed vectors expressing this protein to determine whether its presence could modify the inhibitory activity 1994); these make up two acidic blocks, one N-terminal to residue 12 and the second between residues 36 and of ICP22. The vector was found to be functional, since it was able to phosphorylate both itself and casein. Surpris-69, containing a high proportion of serine/threonine residues ( Fig. 6 ) and at least four S*/T*-X-X-D/E consensus ingly, we observed that UL13 itself was able to inhibit CAT expression under the a4 promoter, suggesting that sequences close to b-turns, potential targets for phosphorylation by protein kinase UL13 and/or CK2 (Pinna, the UL13 gene product might act as a gene expression regulator, probably via phosphorylation of cellular tran-1990) . Moreover, the R/P-R-A-P/S-R sequence, a site of nucleotidylylation of ICP22, an event which apparently scriptional factors. Although either expression vector (pEX22 or pEXUL13) was able to inhibit CAT expression takes place at the IE stage of infection (Mitchell et al., 1994) , is also located in this part of the molecule between under the control of the a4 promoter, their effects were not additive. Furthermore, when present at a particular residues 76 and 80. In addition, as found with EHV1 (Holden et al., 1992) , molar ratio, a reproducible significant reduction of CAT inhibition was seen. Similar results were seen when a new transcript, 3 coterminal with the mRNA encoded by the a22 gene and directing the synthesis of a new pCMV22 was used instead of pEX22. The ratio of the two proteins required to produce partial reversal of inhibition protein corresponding to the C-terminal part of ICP22, has recently been found (Carter and Roizman, 1996) . The suggests a stoichiometric interaction, as seen with other protein kinases, such as casein kinase II (CK2) (Meisner authors postulate that ICP22 encodes at least two sets of functions, the first mapping to the C-terminal half of and Czech, 1991) and cAMP protein kinase (Jesse Chan et al., 1982) . the molecule and responsible for the wild-type phenotype absent from cells infected with R325 (Sears et al., 1985) In our Western blot experiments, using specific antiserum, several forms of ICP22 were seen, with the band or 22n199 (Rice et al., 1995) mutants and the second mapping in the N-terminal region, which may be moduratios differing between transfected and infected COS cells and the faster migrating band being dominant in lated by nucleotidylylation by CK2 and phosphorylation by viral protein kinases (UL13 and US3). The modulation transfected cells (Fig. 1) ; this band, corresponding to the unprocessed molecule, is the only form found in cells of IE expression by phosphorylation of ICP22, like the phosphorylation of the CTD domain of polymerase II ininfected by a UL13-deleted mutant and in cells infected by wild-type virus in the presence of cycloheximide volving ICP22, also appears to be cell-type-independent (since identical results were seen in both COS and Rat1 . Thus, in the transient experiments performed in the absence of UL13, ICP22 was either cells) and is probably related to the N-terminal part of ICP22. nonphosphorylated or less phosphorylated and had undergone less maturation than in infected cells.
On the basis of these and our own findings, we suggest that, at the IE infection stage, ICP22 is either nonDuring infection, the large subunit of polymerase II FIG. 6 . Predicted secondary structure, distribution of acidic and basic residues, and amino acid sequence of ICP22. The amino acid sequences were analyzed according to Garnier et al. (1978) . Three conformational states are shown: a helix ("), sheet (---), and b turn (ÅÅÅ), with the blank regions being coil strands. The middle part of the figure shows basic and acidic residues (above and below the line, respectively). Individual residues are indicated by the length of the lines (E ú D and R ú K ú H), as previously reported (Zhang and Leader, 1990) . The lowest part of the figure shows the amino acid sequence of ICP22. Specific amino acids involved in helices are underlined and the S*/T*-X-X-E/D sequences (Meisner and Czech, 1991) are indicated in bold and underlined. phosphorylated or only slightly phosphorylated and can low levels of phosphorylation. Our data probably demonstrate a mechanism which might be difficult to observe act as a repressor of IE expression, while, at a later stage, it is modified, mainly by newly synthesized viral in infected cells, either because phosphorylation might be cycling on and off (Wilcox et al., 1980) or because protein kinases UL13, resulting in both the loss of inhibitory effect and its involvement in late expression at the other viral factors might hide, or compensate for, the effect. In addition, the regulatory function of this protein transcriptional or posttranscriptional level as previously observed . This mechanism is not is probably related not only to its posttranslational modification but also to its subcellular localization, which itself yet understood, but ICP22 might, like the ICP22 EHV1 homolog, increase the binding of ICP4 to viral promoters depends, either directly or indirectly, on these modifications. and be involved in the regulation of viral expression (D. J. O'Callaghan, personal communication) or increase the amplification of OriS (our unpublished observations). ACKNOWLEDGMENTS However, if ICP22 is a repressor of IE gene expression, We thank A. Hall for the pEXV3 plasmid, S. Silverstein for the pIGA72, ICP22-deleted mutants (R325 and 22/n199) would be ex-65, 106, and 98 plasmids, G. Tiraby for pUT535, B. Roizman for the pected to express IE proteins more efficiently; this does specific anti-ICP22 antiserum, and A. Davison for the specific anti-UL13 not seem to be the case . In fact,
